Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

Repeatability of published microarray gene expression analyses

(2009) John P A Ioannidis et al.   NATURE GENETICS

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML

(2008) L. Bullinger et al.   BLOOD

An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase

(2008) Alexander Kohlmann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Intraplatform Reproducibility and Technical Precision of Gene Expression Profiling in 4 Laboratories Investigating 160 Leukemia Samples: The DACH Study

(2008) A. Kohlmann et al.   CLINICAL CHEMISTRY

Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

(2008) R. G.W. Verhaak et al.   HAEMATOLOGICA

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia

(2008) T. Haferlach   Hematology-American Society of Hematology Education Program